Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. On May 4, 2010 Cadence resubmitted a New Drug Application for its investigational product candidate, OFIRMEVTM (acetaminophen) injection for the treatment of pain and fever in adults and children. The FDA has assigned a new Prescription Drug User Fee Act (PDUFA) action date for OFIRMEV of November 4, 2010.

Recent Milestones
edit

Cadence Pharmaceuticals acquired Incline Therapeutics for $285M. (6/22/10)

Posted 6/22/10 at 7:29pm via tradingmarkets.com
Cadence Pharmaceuticals added Theodore R. Schroeder as President & CEO.

Posted 6/22/10 at 7:28pm
Cadence Pharmaceuticals added William R. LaRue as Senior Vice President, Chief Financial Officer, Treasurer and Assistant Secretary.

Posted 3/13/13 at 3:47am